| abstract |
Novel 16-membered macrolide derivatives represented by the general formula (I) and being effective against erythromycin-resistant Gram-positive bacteria and so on; or pharmaceutically acceptable salts thereof: (I) wherein R is hydrogen, alkylcarbonyl, alkyl, or arylalkenyl; R0 is hydrogen or alkylcarbonyl; R?1 and R2¿ are each independently hydrogen or alkylcarbonyl; and R?3 and R4¿ are each independently hydrogen, alkyl, alkylcarbonyl, aralkylcarbonyl, aralkyl, arylalkenyl, heterocycle-alkyl, or heterocycle-alkenyl. |